Rhizen Pharmaceuticals

April 11, 2018

Tenalisib Receives FDA Orphan Drug Status for Treatment of Cutaneous T-cell Lymphoma

News

The U.S. Food and Drug Administration has granted orphan drug status to investigational therapy tenalisib (RP6530) for the treatment of cutaneous T-cell lymphoma, Rhizen Pharmaceuticals announced. In December, the therapy also received orphan ... Read more

December 18, 2017

Rhizen’s Tenalisib Receives FDA Fast Track Status for Peripheral T-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to the tenalisib (RP6530), Rhizen Pharmaceuticals‘ PI3K delta/gamma blocker, for the treatment of patients with relapsed or refractory peripheral ... Read more